
Emestedastat did not significantly slow disease progression, but a prespecified analysis showed a higher rate of zero CDR-SB progression.
New tools for the armamentarium: a patient self-management app, a retinal imaging system, and a computer program for Alzheimer diagnosis.
View the slides in PDF format.



